Abstract:Radiation for Graves’ ophthalmopathy (GO) has traditionally utilized lateral opposed fields (LOF) or three-dimensional conformal radiotherapy (3DCRT) techniques. The current study was conducted to report clinical outcomes and therapeutic efficacy of intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) in treating GO patients. A total of 113 and 246 GO patients were treated with VMAT and IMRT (including 46 patients treated with the EDGE radiosurgery system) as the initial local therapy between July 2010 and May 2018. The radiation dose was 20Gy given in 10 fractions within 10 working days. Dosimetric comparison between the three radiation methods was conducted. Immediate and long-term treatment response was evaluated by GO severity score in each category of symptoms. Acute and chronic post-radiotherapy complications were also recorded to assess the safety. Logistic regression analysis was conducted to identify possible predictive factors for treatment response. Symptom severity score decreased significantly from the start of treatment to 6 months post-radiotherapy (P<0.01). In total, 184 (74.8%) and 79 (69.8%) patients in the IMRT and VMAT group experienced improvement of GO symptoms in the first 6 months, and only 10 (4.1%) and 7 (6.2%) patients in the two groups suffered recurrence of the GO symptoms during the subsequent follow-ups. Orbital pain, tearing and extraocular muscle dysfunction responded best to radiotherapy, while proptosis and blurred vision were the most refractory symptoms. Acute complications were minimal and self-limited, and mainly included intermittent eye redness (8.1%), increased milphosis or madarosis (20.8%), sideburns hair loss (17.3%), and pseudo-progression of GO symptoms (12.1%). Long-term complications included: chronic xerophthalmias (6.7%), cataract (1.4%), and were managed medically. Radiation retinopathy and secondary malignancy was not noted in the cohort. Although the dosimetric comparison suggested a significantly lower radiation dose to the lens and optic nerves among the patients receiving IMRT by EDGE system, we did not find significant difference in treatment outcomes and complications between the three radiation methods. Current smokers (OR 2.92, P=0.003) and symptom duration longer than 18 months (OR 3.17, P=0.012) were identified as independent predictive factors for non-response of GO to the treatments. Precision radiotherapy, including IMRT and VMAT, could serve as a viable option in treating GO, achieving satisfactory symptom control while minimizing acute and late post-radiotherapy complications.

Quality of life of patients with Graves'ophthalopathy after irradiation

Analysis of the Impact of Ambulatory Care Based on Social Support on the Quality of Life of Patients with Graves' Ophthalmopathy

Observation on Treatment of 61 Patients with Graves' Ophthalmopathy

Precision Radiotherapy for Graves’ Ophthalmopathy Outcomes and Predictors of Response

Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population

A Retrospective Study of Clinical Features and Prognosis of Patients with Graves' Disease and Ophthalmopathy.

Clinical Outcomes of Graves’ Ophthalmopathy Treated with Intensity Modulated Radiation Therapy

Clinical analysis of Graves' ophthalmopathy in the elderly

Clinical analysis of Graves' orbitopathy on conformal radiotherapy in 71 cases

Long-term outcomes of inferomedial orbital wall decompression in Graves’ ophthalmopathy in an Asian population: A 30-year retrospective study

Recent Advances in Graves Ophthalmopathy Medical Therapy: a Comprehensive Literature Review.

Treatment Modalities for Graves' Ophthalmopathy

Restoration of vision by combined experimental antithymocyte therapy, and orbital radiation with high-dose steroids for severe, acute, steroid-refractory, congestive thyroid orbitopathy

Approach to the patients with Graves'ophthalmopathy

Graves′ Ophthalmopathy: Emphasis on Assessment

[Driving competency after combined treatment with methylprednisolone and orbital radiotherapy for endocrine orbitopathy]

The Clinical Features of Graves’ Orbitopathy with Elevated Intraocular Pressure

Natural history of graves' orbitopathy after treatment

Protective effects of standard dose prednisone combined with glutamine on Graves ophthalmopathy after 131I treatment

Protective Effects of Standard Dose Prednisone Combined with Glutamine on Graves' Ophthalmopathy after Radioiodine Therapy

The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients